Curebound’s Mission to Accelerate Cancer Cures Amid NIH Funding Cuts

Cancer research faces a pivotal moment as organizations like Curebound step up to fill the gap left by recent National Institutes of Health (NIH) funding cuts. With over $1.8 billion in federal agency grants to the NIH cut in 2025, affecting nearly 700 grants across 24 NIH institutes, the need for alternative funding sources has never been more urgent. Curebound, a nonprofit dedicated to accelerating cures for cancer, has invested over $43 million in collaborative research grants to date, showcasing a commitment to innovative cancer research that could save lives.

Karen Hooper, Chief Operating Officer of Curebound, brings more than 25 years of nonprofit leadership to the organization. Under her guidance, Curebound has focused on funding cutting-edge research, including hosting events like the Concert for Cures, which raised $11.5 million, and the upcoming Curebound Cancer Challenge. These efforts are part of Curebound’s goal to invest $100 million in cancer research, emphasizing the importance of community involvement and collaboration among top scientists and institutions in San Diego’s biotech hub.

The recent NIH funding cuts highlight the critical role of organizations like Curebound in ensuring the continuity of cancer research. Hooper emphasizes the importance of community and connection in the fight against cancer, urging individuals and businesses to get involved through donations, participation in events, or forming fundraising teams. With a vision for a future where cures for cancer are found within our lifetime, Curebound’s work represents hope for millions affected by this disease.

This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Curebound’s Mission to Accelerate Cancer Cures Amid NIH Funding Cuts.